2020年9月，Tarsus再次获得4000万美元融资，投资方包括Vivo Capital、Frazier等。IPO前，Horowitz Limited Partnership VIII持股为12.88%，Vivo Capital Fund IX, L.P.持股为21.4%，Flying L Investments XI, LLC持股为7.95%；Frazier Life Sciences IX, L.P. 持股为11.47%；Visionary Venture Fund持股为5.96...
简介:Tarsus Pharmaceuticals是一家美国临床阶段眼科药物研发商,旨在将创新疗法应用于一系列需要更好解决方案的疾病,从蠕形眼睑睑缘炎和眼保健开始,致力于研发首个用于睑缘炎的药物。 融资历程 3 导出 序号披露日期交易金额融资轮次估值比例投资方新闻来源 12020-10-168800万美元IPO上市-- ...
公司概况 公司名称 Tarsus Pharmaceuticals, Inc. 所属市场 NASDAQ 成立日期 2016 员工人数 244 办公地址 15440 Laguna Canyon Road,Suite 160,Irvine,California,United States 公司网址 http://www.tarsusrx.com 邮政编码 92618 联系电话 949 409 1801 联系传真 - - 公司概况 Tarsus Pharmaceuticals, Inc.是根据特...
By Tarsus Pharmaceuticals Produced by Twitter Facebook Email Recent research indicates that more than half of the 45 million patients who visit eye care clinics in the US each year may have Demodex blepharitis; inflammation of the eyelid caused by the most common human ectoparasite, the Demodex ...
A high-level overview of Tarsus Pharmaceuticals, Inc. (TARS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
TARSTarsus Pharmaceuticals, Inc. Options Chain & Prices 1.94K followers $52.910.91(+1.75%)4:00 PM 12/20/24 NASDAQ |$USD |Post-Market:$52.66-0.25(-0.47%)6:26 PM There are currently no options for TARS People Also Follow SymbolLast PriceChange ...
View Tarsus Pharmaceuticals, Inc. (TARS) capital structure, market cap, total debt, and overall enterprise value. TARS capital structure breakdown.